Pharmacogenomics of Stimulant Treatment Response (PGx-STaR)
Summary
Stimulant medication (Biphentin®, Concerta®) are first-line treatment for children and adolescents with attention deficit/hyperactivity disorder (ADHD) but experiences with these treatments vary from child-to-child. Despite helping many youth, some who use stimulants experience minimal to no benefit, while others experience significant side effects. If a personalized prescribing strategy were available to improve the use of stimulants, we could prevent a lot of suffering and negative outcomes. Unlike other medications prescribed for mental health (e.g., antidepressants) that have genomic markers to guide prescribing, we have limited evidence to help similar personalized prescribing of stimulants. This study aims to identify genetic markers associated with stimulant response and side effects that could be used to improve prescribing and shorten the path to wellness for youth with ADHD.
Eligibility
Eligible ages: 6 to 24
Inclusion criteria:
1. Aged 6 – 24 years
2. Primary diagnosis of Attention Deficit Hyperactivity Disorder (ADHD)
3. Starting psychostimulant Methylphenidate (i.e., Biphentin, Concerta, Foquest or Ritalin XR) treatment.
4. Located in Western Canada (i.e., Alberta, British Columbia, Saskatchewan, Manitoba).
Exclusion criteria:
1. Co-occurring psychotic, bipolar, autism spectrum disorder, tics/tourettes, or eating disorder(s)
2. Significant risk of suicide
3. An intellectual disability diagnosis
4. Past 12-month high-risk alcohol or substance use defined as monthly or more frequent use
5. Enrolled in psychotherapy or brain stimulation-based therapy initiated within 8 weeks of referral, or plans to initiate/change these types of therapies during the study
6. Medically unstable or lacking capacity to provided informed consent
7. Unwillingness to provide saliva or blood sample for genetic analysis
8. History of liver or bone marrow (hematopoietic cell) transplant
Participate
Fill out the following form if you want to participate in this research
UCalgary Notice of Collection
The University of Calgary (UCalgary) respects your privacy and is
committed to ensuring the privacy of all students, staff, and community members. Your personal information is being
collected under the authority of section 4(c) of the Protection of Privacy Act (POPA). It will be collected, used
and disclosed for the purposes outlined in UCalgary’s
Notice of
Collection, Use and Disclosure of Personal Information and managed in accordance with UCalgary’s
Privacy
Management Program.
Your personal information may be input into automated systems to generate content or make decisions,
recommendations, or predictions. If you have questions regarding this notice or UCalgary’s collection,
use, or disclosure of your personal information, please contact
accessandprivacy@ucalgary.ca.
Additional information
Contact information
Physician or self-referral accepted
Principal investigator:
Chad Bousman
Clinical trial:
No
REB-ID:
REB23-0366
External links